Clostridium Difficile Infection (C-Diff)


Enrolling Studies:

Enrollment Closed:

  • A Phase 3 Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of Rebiotix RBX2660 (microbiota suspension) for the Prevention of Recurrent Clostridium difficile Infection

Recently Completed:

  • A Multi-center, Randomized, Double-blind Study to Compare the Efficacy and Safety of Cadazolid versus Vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD)
  • An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (microbiota suspension) for the Treatment of Recurrent Clostridium difficile Infection